E2F1 induces miR-224/452 expression to drive EMT through TXNIP downregulation

EMBO Reports

Volumn 15, Issue 12, 2014, Pages 1315-1329

  Knoll, Susanne ^a   Fürst, Katharina ^a   Kowtharapu, Bhavani ^a   Schmitz, Ulf ^b   Marquardt, Stephan ^a   Wolkenhauer, Olaf ^b   Martin, Hubert ^c   Pützer, Brigitte M ^a  

^a ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

E2F1 transcription factor; epithelial mesenchymal transition; melanoma metastasis; miRNA cluster; thioredoxin interacting protein

Indexed keywords

CYCLIN DEPENDENT KINASE 4; MICRORNA; MICRORNA 224; MICRORNA 452; PROTEIN P16; THIOREDOXIN INTERACTING PROTEIN; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG; CARRIER PROTEIN; E2F1 PROTEIN, HUMAN; MIRN224 MICRORNA, HUMAN; MIRN452 MICRORNA, HUMAN; TXNIP PROTEIN, HUMAN;

ACTIN FILAMENT; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL ADHESION; CELL CONTACT; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEEDBACK SYSTEM; HUMAN; HUMAN TISSUE; MELANOMA CELL; MELANOMA CELL LINE; MELANOMA METASTASIS; METASTATIC MELANOMA; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INDUCTION; STABLE EXPRESSION; TRANSACTIVATION; TUMOR GROWTH; UPREGULATION; CELL LINE; CHROMATIN IMMUNOPRECIPITATION; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MELANOMA; METABOLISM; PHYSIOLOGY; WESTERN BLOTTING;

BLOTTING, WESTERN; CARRIER PROTEINS; CELL LINE; CHROMATIN IMMUNOPRECIPITATION; E2F1 TRANSCRIPTION FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; IN VITRO TECHNIQUES; MELANOMA; MICRORNAS;

EID: 84915733522     PISSN: 1469221X     EISSN: 14693178     Source Type: Journal    
DOI: 10.15252/embr.201439392     Document Type: Article

References (75)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300
2. Soengas MS, Lowe SW, (2003) Apoptosis and melanoma chemoresistance. Oncogene 22: 3138-3151
3. Alla V, Engelmann D, Niemetz A, Pahnke J, Schmidt A, Kunz M, Emmrich S, Steder M, Koczan D, Putzer BM, (2010) E2F1 in melanoma progression and metastasis. J Natl Cancer Inst 102: 127-133
4. Chen HZ, Tsai SY, Leone G, (2009) Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer 9: 785-797
5. Engelmann D, Putzer BM, (2010) Translating DNA damage into cancer cell death-A roadmap for E2F1 apoptotic signalling and opportunities for new drug combinations to overcome chemoresistance. Drug Resist Updat 13: 119-131
6. Lee JS, Leem SH, Lee SY, Kim SC, Park ES, Kim SB, Kim SK, Kim YJ, Kim WJ, Chu IS, (2010) Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J Clin Oncol 28: 2660-2667
7. Tuve S, Wagner SN, Schittek B, Putzer BM, (2004) Alterations of DeltaTA-p 73 splice transcripts during melanoma development and progression. Int J Cancer 108: 162-166
8. Knoll S, Emmrich S, Putzer BM, (2013) The E2F1-miRNA cancer progression network. Adv Exp Med Biol 774: 135-147
9. Esquela-Kerscher A, Slack FJ, (2006) Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269
10. Hauptman N, Glavac D, (2013) MicroRNAs and long non-coding RNAs: prospects in diagnostics and therapy of cancer. Radiol Oncol 47: 311-318
11. Emmrich S, Putzer BM, (2010) Checks and balances: E2F-microRNA crosstalk in cancer control. Cell Cycle 9: 2555-2567
12. van Rooij E, Purcell AL, Levin AA, (2012) Developing microRNA therapeutics. Circ Res 110: 496-507
13. Zhang Y, Takahashi S, Tasaka A, Yoshima T, Ochi H, Chayama K, (2013) Involvement of microRNA-224 in cell proliferation, migration, invasion, and anti-apoptosis in hepatocellular carcinoma. J Gastroenterol Hepatol 28: 565-575
14. Chen PJ, Yeh SH, Liu WH, Lin CC, Huang HC, Chen CL, Chen DS, Chen PJ, (2012) Androgen pathway stimulates microRNA-216a transcription to suppress the tumor suppressor in lung cancer-1 gene in early hepatocarcinogenesis. Hepatology 56: 632-643
15. Gao P, Wong CC, Tung EK, Lee JM, Wong CM, Ng IO, (2011) Deregulation of microRNA expression occurs early and accumulates in early stages of HBV-associated multistep hepatocarcinogenesis. J Hepatol 54: 1177-1184
16. Scisciani C, Vossio S, Guerrieri F, Schinzari V, De Iaco R, D'Onorio de Meo P, Cervello M, Montalto G, Pollicino T, Raimondo G, et al, (2012) Transcriptional regulation of miR-224 upregulated in human HCCs by NFkappaB inflammatory pathways. J Hepatol 56: 855-861
17. Boguslawska J, Wojcicka A, Piekielko-Witkowska A, Master A, Nauman A, (2011) MiR-224 targets the 3′UTR of type 1 5′-iodothyronine deiodinase possibly contributing to tissue hypothyroidism in renal cancer. PLoS ONE 6: e24541
18. Liu H, Brannon AR, Reddy AR, Alexe G, Seiler MW, Arreola A, Oza JH, Yao M, Juan D, Liou LS, et al, (2010) Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma. BMC Syst Biol 4: 51
19. Arndt GM, Dossey L, Cullen LM, Lai A, Druker R, Eisbacher M, Zhang C, Tran N, Fan H, Retzlaff K, et al, (2009) Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer 9: 374
20. Fu J, Tang W, Du P, Wang G, Chen W, Li J, Zhu Y, Gao J, Cui L, (2012) Identifying microRNA-mRNA regulatory network in colorectal cancer by a combination of expression profile and bioinformatics analysis. BMC Syst Biol 6: 68
21. Wang YX, Zhang XY, Zhang BF, Yang CQ, Chen XM, Gao HJ, (2010) Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis. J Dig Dis 11: 50-54
22. Lu S, Wang S, Geng S, Ma S, Liang Z, Jiao B, (2013) Upregulation of microRNA-224 confers a poor prognosis in glioma patients. Clin Transl Oncol 15: 569-574
23. Mian C, Pennelli G, Fassan M, Balistreri M, Barollo S, Cavedon E, Galuppini F, Pizzi M, Vianello F, Pelizzo MR, et al, (2012) MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome. Thyroid 22: 890-896
24. Gokhale A, Kunder R, Goel A, Sarin R, Moiyadi A, Shenoy A, Mamidipally C, Noronha S, Kannan S, Shirsat NV, (2010) Distinctive microRNA signature of medulloblastomas associated with the WNT signaling pathway. J Cancer Res Ther 6: 521-529
25. Scapoli L, Palmieri A, Lo Muzio L, Pezzetti F, Rubini C, Girardi A, Farinella F, Mazzotta M, Carinci F, (2010) MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression. Int J Immunopathol Pharmacol 23: 1229-1234
26. Kim YK, Yu J, Han TS, Park SY, Namkoong B, Kim DH, Hur K, Yoo MW, Lee HJ, Yang HK, et al, (2009) Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. Nucleic Acids Res 37: 1672-1681
27. Madhyastha R, Madhyastha H, Nakajima Y, Omura S, Maruyama M, (2012) MicroRNA signature in diabetic wound healing: promotive role of miR-21 in fibroblast migration. Int Wound J 9: 355-361
28. Graff JW, Powers LS, Dickson AM, Kim J, Reisetter AC, Hassan IH, Kremens K, Gross TJ, Wilson ME, Monick MM, (2012) Cigarette smoking decreases global microRNA expression in human alveolar macrophages. PLoS ONE 7: e44066
29. Dmitriev P, Barat A, Polesskaya A, O'Connell MJ, Robert T, Dessen P, Walsh TA, Lazar V, Turki A, Carnac G, et al, (2013) Simultaneous miRNA and mRNA transcriptome profiling of human myoblasts reveals a novel set of myogenic differentiation-associated miRNAs and their target genes. BMC Genomics 14: 265
30. Fang X, Yoon JG, Li L, Yu W, Shao J, Hua D, Zheng S, Hood L, Goodlett DR, Foltz G, et al, (2011) The SOX2 response program in glioblastoma multiforme: an integrated ChIP-seq, expression microarray, and microRNA analysis. BMC Genomics 12: 11
31. van Schooneveld E, Wouters MC, Van der Auwera I, Peeters DJ, Wildiers H, Van Dam PA, Vergote I, Vermeulen PB, Dirix LY, Van Laere SJ, (2012) Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers. Breast Cancer Res 14: R34
32. Veerla S, Lindgren D, Kvist A, Frigyesi A, Staaf J, Persson H, Liedberg F, Chebil G, Gudjonsson S, Borg A, et al, (2009) MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int J Cancer 124: 2236-2242
33. Puerta-Gil P, Garcia-Baquero R, Jia AY, Ocana S, Alvarez-Mugica M, Alvarez-Ossorio JL, Cordon-Cardo C, Cava F, Sanchez-Carbayo M, (2012) miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer. Am J Pathol 180: 1808-1815
34. Liu SG, Qin XG, Zhao BS, Qi B, Yao WJ, Wang TY, Li HC, Wu XN, (2013) Differential expression of miRNAs in esophageal cancer tissue. Oncol Lett 5: 1639-1642
35. Liu C, Kelnar K, Vlassov AV, Brown D, Wang J, Tang DG, (2012) Distinct microRNA expression profiles in prostate cancer stem/progenitor cells and tumor-suppressive functions of let-7. Cancer Res 72: 3393-3404
36. Sheehy NT, Cordes KR, White MP, Ivey KN, Srivastava D, (2010) The neural crest-enriched microRNA miR-452 regulates epithelial-mesenchymal signaling in the first pharyngeal arch. Development 137: 4307-4316
37. Najafi-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE, Naar AM, (2010) MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 328: 1566-1569
38. Bullock MD, Sayan AE, Packham GK, Mirnezami AH, (2012) MicroRNAs: critical regulators of epithelial to mesenchymal (EMT) and mesenchymal to epithelial transition (MET) in cancer progression. Biol Cell 104: 3-12
39. Sreekumar R, Sayan BS, Mirnezami AH, Sayan AE, (2011) MicroRNA control of invasion and metastasis pathways. Front Genet 2: 58
40. Tam WL, Weinberg RA, (2013) The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med 19: 1438-1449
41. Denecker G, Vandamme N, Akay O, Koludrovic D, Taminau J, Lemeire K, Gheldof A, De Craene B, Van Gele M, Brochez L, et al, (2014) Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression. Cell Death Differ 21: 1250-1261
42. Haynes J, Srivastava J, Madson N, Wittmann T, Barber DL, (2011) Dynamic actin remodeling during epithelial-mesenchymal transition depends on increased moesin expression. Mol Biol Cell 22: 4750-4764
43. Yang JH, Li JH, Shao P, Zhou H, Chen YQ, Qu LH, (2011) starBase: a database for exploring microRNA-mRNA interaction maps from Argonaute CLIP-Seq and Degradome-Seq data. Nucleic Acids Res 39: D202-D209
44. Friedman Y, Naamati G, Linial M, (2010) MiRror: a combinatorial analysis web tool for ensembles of microRNAs and their targets. Bioinformatics 26: 1920-1921
45. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al, (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25: 25-29
46. Zhou J, Chng WJ, (2013) Roles of thioredoxin binding protein (TXNIP) in oxidative stress, apoptosis and cancer. Mitochondrion 13: 163-169
47. Goldberg SF, Miele ME, Hatta N, Takata M, Paquette-Straub C, Freedman LP, Welch DR, (2003) Melanoma metastasis suppression by chromosome 6: evidence for a pathway regulated by CRSP3 and TXNIP. Cancer Res 63: 432-440
48. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM, (2004) ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6: 1-6
49. Nishinaka Y, Nishiyama A, Masutani H, Oka S, Ahsan KM, Nakayama Y, Ishii Y, Nakamura H, Maeda M, Yodoi J, (2004) Loss of thioredoxin-binding protein-2/vitamin D3 up-regulated protein 1 in human T-cell leukemia virus type I-dependent T-cell transformation: implications for adult T-cell leukemia leukemogenesis. Cancer Res 64: 1287-1292
50. Wang Y, Toh HC, Chow P, Chung AY, Meyers DJ, Cole PA, Ooi LL, Lee CG, (2012) MicroRNA-224 is up-regulated in hepatocellular carcinoma through epigenetic mechanisms. FASEB J 26: 3032-3041
51. Kristensen H, Haldrup C, Strand S, Mundbjerg K, Mortensen MM, Thorsen K, Ostenfeld MS, Wild PJ, Arsov C, Goering W, et al, (2014) Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy. Clin Cancer Res 20: 2169-2181
52. Diaz-Lopez A, Moreno-Bueno G, Cano A, (2014) Role of microRNA in epithelial to mesenchymal transition and metastasis and clinical perspectives. Cancer Manag Res 6: 205-216
53. Park SM, Gaur AB, Lengyel E, Peter ME, (2008) The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 22: 894-907
54. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ, (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10: 593-601
55. Korpal M, Lee ES, Hu G, Kang Y, (2008) The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 283: 14910-14914
56. Giricz O, Reynolds PA, Ramnauth A, Liu C, Wang T, Stead L, Childs G, Rohan T, Shapiro N, Fineberg S, et al, (2012) Hsa-miR-375 is differentially expressed during breast lobular neoplasia and promotes loss of mammary acinar polarity. J Pathol 226: 108-119
57. Bolos V, Peinado H, Perez-Moreno MA, Fraga MF, Esteller M, Cano A, (2003) The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci 116: 499-511
58. Satelli A, Li S, (2011) Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci 68: 3033-3046
59. Nishiyama A, Matsui M, Iwata S, Hirota K, Masutani H, Nakamura H, Takagi Y, Sono H, Gon Y, Yodoi J, (1999) Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J Biol Chem 274: 21645-21650
60. Welsh SJ, Bellamy WT, Briehl MM, Powis G, (2002) The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res 62: 5089-5095
61. Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, Kawabata M, Miyazono K, Ichijo H, (1998) Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 17: 2596-2606
62. Liu Y, Min W, (2002) Thioredoxin promotes ASK1 ubiquitination and degradation to inhibit ASK1-mediated apoptosis in a redox activity-independent manner. Circ Res 90: 1259-1266
63. Zhou J, Bi C, Cheong LL, Mahara S, Liu SC, Tay KG, Koh TL, Yu Q, Chng WJ, (2011) The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood 118: 2830-2839
64. Kwon HJ, Won YS, Suh HW, Jeon JH, Shao Y, Yoon SR, Chung JW, Kim TD, Kim HM, Nam KH, et al, (2010) Vitamin D3 upregulated protein 1 suppresses TNF-alpha-induced NF-kappaB activation in hepatocarcinogenesis. J Immunol 185: 3980-3989
65. Sheth SS, Bodnar JS, Ghazalpour A, Thipphavong CK, Tsutsumi S, Tward AD, Demant P, Kodama T, Aburatani H, Lusis AJ, (2006) Hepatocellular carcinoma in Txnip-deficient mice. Oncogene 25: 3528-3536
66. Butler LM, Zhou X, Xu WS, Scher HI, Rifkind RA, Marks PA, Richon VM, (2002) The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA 99: 11700-11705
67. Nishizawa K, Nishiyama H, Matsui Y, Kobayashi T, Saito R, Kotani H, Masutani H, Oishi S, Toda Y, Fujii N, et al, (2011) Thioredoxin-interacting protein suppresses bladder carcinogenesis. Carcinogenesis 32: 1459-1466
68. Masaki S, Masutani H, Yoshihara E, Yodoi J, (2012) Deficiency of thioredoxin binding protein-2 (TBP-2) enhances TGF-beta signaling and promotes epithelial to mesenchymal transition. PLoS ONE 7: e39900
69. Wei J, Shi Y, Hou Y, Ren Y, Du C, Zhang L, Li Y, Duan H, (2013) Knockdown of thioredoxin-interacting protein ameliorates high glucose-induced epithelial to mesenchymal transition in renal tubular epithelial cells. Cell Signal 25: 2788-2796
70. Kaimul AM, Nakamura H, Masutani H, Yodoi J, (2007) Thioredoxin and thioredoxin-binding protein-2 in cancer and metabolic syndrome. Free Radic Biol Med 43: 861-868
71. Glasauer A, Chandel NS, (2014) Targeting antioxidants for cancer therapy. Biochem Pharmacol 92: 90-101
72. Patwari P, Lee RT, (2012) An expanded family of arrestins regulate metabolism. Trends Endocrinol Metab 23: 216-222
73. Alla V, Kowtharapu BS, Engelmann D, Emmrich S, Schmitz U, Steder M, Putzer BM, (2012) E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73-miR-205 circuitry. Cell Cycle 11: 3067-3078
74. Knoll S, Furst K, Thomas S, Villanueva Baselga S, Stoll A, Schaefer S, Putzer BM, (2011) Dissection of cell context-dependent interactions between HBx and p53 family members in regulation of apoptosis: a role for HBV-induced HCC. Cell Cycle 10: 3554-3565
75. Racek T, Buhlmann S, Rust F, Knoll S, Alla V, Putzer BM, (2008) Transcriptional repression of the prosurvival endoplasmic reticulum chaperone GRP78/BIP by E2F1. J Biol Chem 283: 34305-34314